Anti-GFAP Purified

Anti-GFAP Purified
Regulatory status
RUO
Antigen
GFAP
Clone
GF-02
Format
Purified
Reactivity
Human, Pig
Variant
0.1 mg
11-441-C100
In stock
160.00 USD

0.025 mg
11-441-C025
Delivery 1 week
80.00 USD
Variant
0.1 mg
11-261-C100
In stock
160.00 USD

0.1 mg
11-261-C100
In stock
80.00 USD
Product details
Description
Images
References
Isotype
Mouse IgM
Specificity
The mouse monoclonal antibody GF-02 exclusively reacts with intact GFAP molecules. GFAP is the principal marker of astroglial cells in the central nervous system; it is specifically expressed in satellite cells in peripheral ganglia and in non myelinating Schwann cells in peripheral nerves. The GFAP protein runs on gels at ~55 kDa protein, usually associated with lower Mw bands which are thought to be proteolytic fragments and alternate transcripts from the single gene.
Application details
Western blotting: Recommended dilution: 1-2 μg/ml.
Reactivity
Human, Pig
Immunogen
Pellet of porcine brain cold-stable proteins after depolymerization of microtubules.
Concentration
1 mg/ml
Preparation
Purified by sequential steps of physicochemical fractionation (differential precipitation and solid-phase chromatography methods).
Formulation
Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
GFAP, ALXDRD
Antigen description
GFAP (glial fibrillary acidic protein) was discovered by Bignami et al. (1972) as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes. Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein probably also plays a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the insulating layer (myelin) that covers nerve cells. Additionally, GFAP protein may assist in maintaining the protective barrier that allows only certain substances to pass between blood vessels and the brain (blood-brain barrier).In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’s disease, epilepsy and multiple sclerosis.Antibodies to GFAP are therefore very useful as markers of astrocytic cells and neural stem cells and for distinguishing of neoplasms of astrocytic origin from other neoplasms in the central nervous system. Finally, Alexander's disease was recently shown to be caused by point mutations in protein coding region of the GFAP gene (Brenner et al., 2001). All forms of Alexander disease are characterized by the presence of Rosenthal fibers, which are GFAP containing cytoplasmic inclusions found in astrocytes.
Entrez Gene ID 2670
UniProt ID P14136
11-441_WB
Western blotting analysis of human GFAP using mouse monoclonal antibody GF-02 on lysates of Neuro 2a and HEK 293T cells under reducing and non-reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse anti-GFAP monoclonal antibody followed by IRDye800-conjugated anti-mouse secondary antibody. A specific band was detected for GFAP at approximately 54 kDa.
11-441_WB1
Western blotting analysis (reducing conditions) of GFAP in porcine brain lysate. Lane 1: immunostaining with anti-GFAP (GF-02) Lane 2: immunostaining with Isotype mouse IgM control (PFR-03; cat. no. 11-803-C100)

General references:

Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A: Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001 Jan;27(1):117-20.
PubMed

Product specific references:

Porchet R, Probst A, Bouras C, Draberova E, Draber P, Riederer BM: Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics. 2003 Aug;3(8):1476-85.
PubMed
Variant
0.1 mg
11-441-C100
In stock
160.00 USD

0.025 mg
11-441-C025
Delivery 1 week
80.00 USD
Variant
0.1 mg
11-261-C100
In stock
160.00 USD

0.1 mg
11-261-C100
In stock
80.00 USD